12 Month Price Forecast For GKOS
Distance to GKOS Price Forecasts
GKOS Price Momentum
๐ค Considering Glaukos (GKOS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 12:51 AM UTC
GKOS Analyst Ratings & Price Targets
Based on our analysis of 19 Wall Street analysts, GKOS has a consensus that is bullish. The median price target is $160.00, with forecasts ranging from $120.00 to $185.00. Currently, there are 11 Buy ratings, 2 Hold ratings, and 1 Sell ratings.
With GKOS currently trading at $154.32, the median price forecast suggests a 3.7% upside. The most optimistic forecast comes from Richard Newitter at Truist Securities, projecting a 19.9% upside, while Patrick Wood at Morgan Stanley provides the most conservative target, suggesting a -22.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GKOS Analyst Consensus
GKOS Price Target Range
Latest GKOS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GKOS.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 27, 2025 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $180.00 |
Dec 31, 2024 | Stifel | Thomas Stephan | Buy | Maintains | $175.00 |
Dec 18, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $185.00 |
Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Upgrade | $162.00 |
Dec 11, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $153.00 |
Dec 6, 2024 | UBS | Danielle Antalffy | Buy | Initiates | $182.00 |
Dec 2, 2024 | Stifel | Thomas Stephan | Buy | Maintains | $153.00 |
Dec 2, 2024 | Morgan Stanley | Patrick Wood | Underweight | Downgrade | $120.00 |
Nov 26, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $149.00 |
Nov 5, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $145.00 |
Nov 5, 2024 | JP Morgan | Allen Gong | Overweight | Maintains | $145.00 |
Oct 14, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $152.00 |
Sep 3, 2024 | Stifel | Thomas Stephan | Buy | Maintains | $145.00 |
Aug 28, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $139.00 |
Aug 1, 2024 | Truist Securities | Richard Newitter | Buy | Reiterates | $145.00 |
Aug 1, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $140.00 |
Aug 1, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $135.00 |
Aug 1, 2024 | Needham | David Saxon | Buy | Maintains | $137.00 |
Jul 16, 2024 | Truist Securities | Samuel Brodovsky | Buy | Maintains | $141.00 |
Jul 15, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $131.00 |
Stocks Similar to Glaukos Corp
The following stocks are similar to Glaukos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Glaukos Corp (GKOS) Financial Data
Glaukos Corp has a market capitalization of $8.51B with a P/E ratio of -56.5x. The company generates $360.35M in trailing twelve-month revenue with a -41.5% profit margin.
Revenue growth is +23.9% quarter-over-quarter, while maintaining an operating margin of -25.5% and return on equity of -26.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Glaukos Corp (GKOS) Company Overview
About Glaukos Corp
Develops therapies for eye diseases.
The company generates revenue by selling innovative medical devices and pharmaceutical therapies specifically designed for treating glaucoma and other ocular conditions. Its flagship products include micro-bypass stents and intracameral therapies, which are marketed directly and through distributors.
Founded in 1998 and based in Aliso Viejo, California, the company has a strong product pipeline addressing unmet medical needs in ophthalmology, positioning it well for future growth in a specialized market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
907
CEO
Mr. Thomas William Burns
Country
United States
IPO Year
2015
Website
www.glaukos.comGlaukos Corp (GKOS) Latest News & Analysis
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
13 days agoGlaukos Corporation will release its Q4 and full year 2024 financial results on February 20, 2025, after market close, with a conference call at 1:30 p.m. PT.
Glaukos Corporation's upcoming financial results release could impact stock performance and investor sentiment, particularly regarding growth in ophthalmic therapies and market positioning.
Glaukos' iDose TR provides effective IOP reduction and safety for glaucoma treatment. The company is also advancing its next-gen iDose TREX system.
Glaukos' advancements in glaucoma treatment enhance its market position, potentially increasing revenue and investor confidence, while ongoing innovations may boost future growth.
Glaukos Corporation announced positive 36-month follow-up results from Phase 3 trials for its iDoseยฎ platform, focusing on glaucoma treatments.
Positive clinical updates for Glaukos' iDose platform indicate potential for increased market share and revenue growth, enhancing investor confidence in the company's future performance.
GKOS is experiencing strong product demand and expanding into new markets, supported by a promising development pipeline.
Strong product demand and market expansion indicate potential revenue growth for GKOS, while a solid development pipeline suggests future profitability, attracting investor interest.
Investors are optimistic about GKOS due to its strong product portfolio and robust demand, along with expansion into new markets.
Optimism around GKOS' product portfolio and market expansion signals potential revenue growth, which can boost stock performance and attract more investment interest.
Top Wall Street analysts have updated their ratings on several key stocks. For detailed information on all changes, refer to the analyst ratings page.
Changes in analyst ratings can influence stock prices and investor sentiment, impacting market trends and potential investment decisions for those specific companies.
Frequently Asked Questions About GKOS Stock
What is Glaukos Corp's (GKOS) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Glaukos Corp (GKOS) has a median price target of $160.00. The highest price target is $185.00 and the lowest is $120.00.
Is GKOS stock a good investment in 2025?
According to current analyst ratings, GKOS has 11 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $154.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GKOS stock?
Wall Street analysts predict GKOS stock could reach $160.00 in the next 12 months. This represents a 3.7% increase from the current price of $154.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Glaukos Corp's business model?
The company generates revenue by selling innovative medical devices and pharmaceutical therapies specifically designed for treating glaucoma and other ocular conditions. Its flagship products include micro-bypass stents and intracameral therapies, which are marketed directly and through distributors.
What is the highest forecasted price for GKOS Glaukos Corp?
The highest price target for GKOS is $185.00 from Richard Newitter at Truist Securities, which represents a 19.9% increase from the current price of $154.32.
What is the lowest forecasted price for GKOS Glaukos Corp?
The lowest price target for GKOS is $120.00 from Patrick Wood at Morgan Stanley, which represents a -22.2% decrease from the current price of $154.32.
What is the overall GKOS consensus from analysts for Glaukos Corp?
The overall analyst consensus for GKOS is bullish. Out of 19 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $160.00.
How accurate are GKOS stock price projections?
Stock price projections, including those for Glaukos Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.